 Myriad Genetics has also been involved in litigation in Australia over the patentability of DNA sequences.Regarding BRCA1, the company succeeded in the Federal Court, both at first instance and on appeal to the full court, but in October 2015 lost in a unanimous decision of the High Court, "D'Arcy v Myriad Genetics Inc".In Australia an invention is patentable if, to begin with, it is a "manner of manufacture".